

1 **Title:** Maternal MAPK/Erk signaling regulates embryonic dorsal organizer formation in
2 zebrafish

3 **Authors:** Tong Lv^{1, #}, Yaping Meng^{1, 2 #}, Jing Chen³, Fangjie Cao^{1, 4}, Yaqi Li^{1, 5}, Shunji Jia^{1, 6},
4 Xiaotong Wu^{1, *}, Anming Meng^{1, *}

5 **Affiliations:**

- 6 1. Laboratory of Molecular Developmental Biology, State Key Laboratory of Membrane Biology,
7 Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University,
8 Beijing 100084, China.
- 9 2. Department of Cardiology & Liangzhu laboratory, The Second Affiliated Hospital, School of
10 Medicine, Zhejiang University, Hangzhou 310009, China; State Key Laboratory of
11 Transvascular Implantation Devices, Hangzhou 310009, China.
- 12 3. Department of Pediatric Surgery and Laboratory of Pediatric Surgery, West China Hospital,
13 Sichuan University, Chengdu 610041, China.
- 14 4. Institute of Eco-environmental and Soil Sciences, Guangdong Academy of Sciences,
15 Guangzhou 510650, China.
- 16 5. Department of Histology and Embryology, Naval Medical University, Shanghai 200433, China.
- 17 6. State Key Laboratory of Molecular Developmental Biology, Institute of Genetics and
18 Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China.

19

20 #These authors equally contributed to this work.

21 *Correspondence should be addressed to: Anming Meng (mengam@mail.tsinghua.edu.cn) and
22 Xiaotong Wu (wuxt@mail.tsinghua.edu.cn)

23

24 **Supplementary Material file includes:**


25 Supplementary Figures S1-S5

26 Supplementary Tables S1-S3


27

Supplementary Figure 1

a



b




28

29 **Supplementary Fig. 1. | Expression of *erk1* and *erk2* during early embryogenesis.** a Expression
 30 levels of *erk1* and *erk2* at the indicated stages of embryonic development, extracted from RNA-
 31 seq data ⁴⁶. b Expression patterns of *erk1* and *erk2* during early embryonic development, examined
 32 by WISH. Note that *erk1* and *erk2* mRNAs are ubiquitously distributed in the blastoderm.

33

Supplementary Figure 2




34

35 **Supplementary Fig. 2. | Distribution of pErk1/2 and total Erk1/2 proteins during early**
36 **embryogenesis.** pErk1/2 and total Erk1/2 were detected by immunostaining with specific
37 antibodies (green) along with nuclei stained by DAPI (blue). Immunostained embryos were
38 observed by confocal microscopy. Embryos were viewed from the animal pole.

39

Supplementary Figure 3




40

41 **Supplementary Fig. 3. | Inhibition of MAPK/Erk signaling suppresses Erk1/2 activation and**
 42 **dorsal organizer formation during early embryonic development. a** Erk1/2 activation in WT
 43 embryos is effectively suppressed by treatment with 20 μM of the MAPK/Erk inhibitor PD, while
 44 total Erk1/2 level remains unaltered. The proteins shown were detected by Western blotting. **b**
 45 Postfertilization inhibition of Erk1/2 activation impairs organizer formation. *Tg(gsc:EGFP)*
 46 transgenic embryos were treated with DMSO or 20 μM PD at the 1c stage and washed at the shield
 47 stage, followed by incubation in fresh culture water until the desired stages. Embryos were
 48 observed under a fluorescent dissection microscope. The ratio of embryos with the representative
 49 morphology was indicated. Note that EGFP expressed in the organizer in PD-treated embryos at
 50 the shield stage was completely abolished and most of the treated embryos died during the
 51 midsegmentation period.

52

Supplementary Figure 4



53

54

55

56

57

58


59

60

61

Supplementary Fig. 4. | Effects of *erk2* or *caerk2* overexpression on dorsal and ventral markers in *Mhwa* mutants. a Expression levels of the dorsal markers (*boz*, *chd*, and *gsc*) and ventral markers (*bmp4* and *eve1*) in WT, *Mhwa*, and *erk2*- or *caerk2*-injected *Mhwa* embryos at the shield stages. 1c stage embryos were injected with 200 pg (per embryo) *erk2* or *caerk2* mRNA and collected at the shield stage for qRT-PCR analysis. Data were mean ± s.d. from three replicates; two-tailed unpaired Student’s *t*-test was performed with ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$, and ns with $P > 0.05$.

Supplementary Figure 5



62

63 **Supplementary Fig. 5. | Erk1/2 signaling functions in dorsal organizer and body axis**
 64 **formation through Jun and Fos.** **a** Effects of *jun/fos* overexpression on expression levels of the
 65 organizer markers *gsc* and *chd* in WT and *Mhwa* embryos at the shield stage. Embryos were
 66 injected with *jun* and *fos* mRNAs (each 200 pg per embryo) at the 1c stage and collected at the
 67 shield stage for qRT-PCR analysis. Data were mean \pm s.d. from three replicates; two-tailed
 68 unpaired Student's *t*-test was performed with * $P < 0.05$, *** $P < 0.001$, **** $P < 0.0001$, and ns
 69 with $P > 0.05$. **b** Overexpression of *jun/fos* in *Mhwa* mutant embryos is unable to restore the body
 70 axis. *Mhwa* mutant embryos were injected with *jun* and *fos* mRNAs (each 200 pg per embryo) at
 71 the 1c stage and observed at 24 hpf. The ratio of embryos with the representative morphology was
 72 indicated. **c** WISH-detected expression patterns of *chd* and *evel* in shield stage *Mhwa* embryos co-
 73 injected with *caerk2* and *dnjun* mRNAs. 1c stage embryos were injected with 200 pg (per embryo)
 74 *caerk2* mRNA and 200 pg *dnjun* mRNA (same for **d**). **d** Morphological changes of 24-hpf *Mhwa*
 75 embryos injected with *caerk2* mRNA or *caerk2* mRNA plus *dnjun* mRNAs. n, number of observed
 76 embryos.

77

78 **Supplementary Table S1.**
79 **Sequences of primers for genotyping *erk1*^{-/-} and *erk2*^{-/-} mutants.**

Table S1 Sequences of primers for genotyping

Mutants	Sequences (5'-3')
<i>erk1</i> -M1 (-47 bp)	Forward: GATCTGAAAGCAAATACGAGGC
<i>erk1</i> -M2 (-8 bp)	Reverse: TACTGGAGATCAGTGTATCGGG
<i>erk2</i> -M3 (-5 bp)	Forward: ACCGAGTCTTCGGTTCAGTTTA Reverse: GTAGGAGAGGTTGCTGTAACGC
<i>erk2</i> -M4 (-2 bp)	Forward: GTACAAGCTGTTGAAGACGCAG Reverse: TAACGTCCAAGATGAGACCCTT

80
81

82 **Supplementary Table S2.**

83 **Sequences of probe antisense primers for whole-mount in situ hybridization.**

Table S2 Sequences of probe primers for whole-mount in situ hybridization

Genes	Sequences (5'-3')
<i>erk1</i>	Sense: GCCAGGAACTACCTCCAG Antisense: TAATACGACTCACTATAGGGGCCCAAAGTAGCGCACAGC
<i>erk2</i>	Sense: CATGACCACACCGGCTTCC Antisense: TAATACGACTCACTATAGGGCGAAAGAGGAGCACAGCGC

84

85

86 **Supplementary Table S3.**
 87 **Sequences of primers for quantitative RT-PCR analysis of gene expression.**

Table S3 Sequences of primers for quantitative RT-PCR

Genes	Sequences (5'-3')
<i>erk1</i>	Forward: GGATGGTCTGCTCAGCTTTTG Reverse: CCTGTACGATATAGACATCCCTC
<i>erk2</i>	Forward: GATGAAAGACGTTTACATCGTACAGG Reverse: GCCCAAATCACAGATCTTGAGGTC
<i>pla2g4aa</i>	Forward: CGGCAAGACAACCAAAGTG Reverse: GTTGCACAGTCAAACACGCC
<i>crtc3</i>	Forward: CGGAACGCCAGCATGAATG Reverse: GCTCAGATTGGGATACCCAGC
<i>elk1</i>	Forward: GCATGAGATGCGAGTTTGTGAG Reverse: CCAACAGACGGAGGCTTTATG
<i>hwa</i>	Forward: GCATCATCCCACAGGAGAAC Reverse: GTGACGTAACCTGGGTCGTA
<i>boz</i>	Forward: ACACCAGCAGGCAAACAGCA Reverse: CAACCGGCTACGGCATAAGG
<i>chd</i>	Forward: AGACTGCTGTAAGGAGTGTCCCTC Reverse: CCATGAAGTCCTCTATGCATTCCG
<i>gsc</i>	Forward: TCCAGCGCCGAACTTACAAT Reverse: GCGCTGTCATAACCTGTAGGAA
<i>bmp4</i>	Forward: CCAACACCGTGAGAGGATTCC Reverse: TCCACAGCAAGGCCATGATTAG
<i>eve1</i>	Forward: ATGCCAGAGGACAGGGAGTT Reverse: GAGTCAGCTGTTCCCTCGTG
<i>β-actin</i>	Forward: ATGGATGATGAAATTGCCGCAC Reverse: ACCATCACCAGAGTCCATCACG

88